{ "items": [ "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib.\n

\n \n \n \n \n\n \n \n \n

Rampotas A. et al, (2023), Blood

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Loss of endothelial membrane KIT ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells.\n

\n \n \n \n \n\n \n \n \n

Matsuoka S. et al, (2023), Blood, 142, 1622 - 1632

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.\n

\n \n \n \n \n\n \n \n \n

McLornan DP. et al, (2023), Br J Haematol

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Erythroid differentiation enhances RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts.\n

\n \n \n \n \n\n \n \n \n

Moura PL. et al, (2023), Cancer research

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.\n

\n \n \n \n \n\n \n \n \n

Mesa RA. et al, (2023), Hemasphere, 7

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.\n

\n \n \n \n \n\n \n \n \n

O'Sullivan JM. et al, (2023), Leukemia

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner.\n

\n \n \n \n \n\n \n \n \n

Luis TC. et al, (2023), Nat Commun, 14

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.\n

\n \n \n \n \n\n \n \n \n

Rodriguez-Meira A. et al, (2023), Nat Genet

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Systemically produced Kit ligand is sufficient to maintain mouse hematopoietic stem cells\n

\n \n \n \n \n\n \n \n \n

NERLOV C. et al, (2023), Blood

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.\n

\n \n \n \n \n\n \n \n \n

Harrison C. et al, (2023), Haematologica, 108, 1960 - 1964

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.\n

\n \n \n \n \n\n \n \n \n

Harrison CN. et al, (2023), J Clin Oncol

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.\n

\n \n \n \n \n\n \n \n \n

Mesa RA. et al, (2023), Cancer Med, 12, 10612 - 10624

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Quantifying inherent predictability and spatial synchrony in the aphid vector Myzus persicae: field-scale patterns of abundance and regional forecasting error in the UK.\n

\n \n \n \n \n\n \n \n \n

Bell JR. et al, (2023), Pest Manag Sci, 79, 1331 - 1341

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n MARVEL: an integrated alternative splicing analysis platform for single-cell RNA sequencing data.\n

\n \n \n \n \n\n \n \n \n

Wen WX. et al, (2023), Nucleic Acids Res, 51

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Na\u00efve Myelofibrosis.\n

\n \n \n \n \n\n \n \n \n

Mascarenhas J. et al, (2023), J Clin Oncol

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.\n

\n \n \n \n \n\n \n \n \n

Ryou H. et al, (2023), Leukemia

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n ACCELERATED RNA SPLICING DYNAMICS DURING ERYTHROID DIFFERENTIATION AMPLIFY MIS-SPLICING IN SF3B1-MUTANT MDS-RS\n

\n \n \n \n \n\n \n \n \n

Moura P. et al, (2023), LEUKEMIA RESEARCH, 128

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n CHROMOTHRIPSIS AND LEUKEMIC TRANSFORMATION IN MPN\n

\n \n \n \n \n\n \n \n \n

Brierley C. et al, (2023), EXPERIMENTAL HEMATOLOGY, 124, S65 - S65

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A\n

\n \n \n \n \n\n \n \n \n

Brierley CK. et al, (2023), BLOOD, 142

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Impact of momelotinib on patient-reported quality of life for patients with myelofibrosis from MOMENTUM\n

\n \n \n \n \n\n \n \n \n

Rinaldi C. et al, (2023), BRITISH JOURNAL OF HAEMATOLOGY, 201, 84 - 84

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }